Approval · Notice of Compliance 29246 · 2022
PMS-RANITIDINE: Notice of Compliance 29246
Issued October 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29246
- Date
- October 20, 2022
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in the specification for the drug product, addition of a test
- Canadian reference product
- ZANTAC (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-RANITIDINE | Not yet assigned | — |
Medicinal ingredients
- RANITIDINE 150 MG per TAB
- RANITIDINE 300 MG per TAB